| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
1,095,971,000 |
| Market
Cap: |
18.19(B) |
| Last
Volume: |
6,583,979 |
Avg
Vol: |
10,637,630 |
| 52
Week Range: |
$7.2 - $17.09 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ-100 |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Teva Pharmaceutical Industries is a pharmaceutical company. Co. operates through three segments: North America, which includes the U.S. and Canada; Europe, which includes the European Union and certain other European countries; and International Markets, which includes all countries in which Co. operates other than those in Co.'s North America and Europe segments. Co.'s products include: AUSTEDO; AJOVY (anti calcitonin gene-related peptide); COPAXONE; BENDEKA and TREANDA; ProAir HFA; ProAir RespiClick; QVAR; QVAR RediHaler; ProAir Digihaler; ArmonAir Digihaler; AirDuo Digihaler; BRALTUS®; CINQAIR/CINQAERO; and AirDuo RespiClick.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
441,140 |
720,697 |
810,545 |
1,346,844 |
| Total Sell Value |
$6,065,172 |
$9,700,206 |
$10,499,443 |
$15,688,359 |
| Total People Sold |
8 |
8 |
8 |
10 |
| Total Sell Transactions |
14 |
17 |
20 |
34 |
| End Date |
2024-02-25 |
2023-11-24 |
2023-05-26 |
2022-05-26 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Mcclellan Michael James |
EVP, Chief Financial Officer |
• – – |
2019-03-04 |
4 |
AS |
$16.88 |
$6,129 |
D/D |
(363) |
12,330 |
|
- |
|
| Griffin Deborah A |
Chief Accounting Officer |
• – – |
2019-03-04 |
4 |
S |
$16.88 |
$69,340 |
D/D |
(4,107) |
0 |
|
- |
|
| Nazzi Gianfranco |
EVP, Growth Markets Commercial |
• – – |
2019-03-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,399 |
8,404 |
|
- |
|
| Ogrady Brendan P. |
EVP, North America Commercial |
• – – |
2019-03-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,166 |
2,554 |
|
- |
|
| Daniell Richard |
Exec. VP, European Commercial |
• – – |
2019-03-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,098 |
2,098 |
|
- |
|
| Dethlefs Sven |
EVP Global Marketing&Portfolio |
• – – |
2019-03-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,399 |
8,664 |
|
- |
|
| Mcclellan Michael James |
EVP, Chief Financial Officer |
• – – |
2019-03-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,049 |
12,693 |
|
- |
|
| Griffin Deborah A |
Chief Accounting Officer |
• – – |
2019-03-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,166 |
4,107 |
|
- |
|
| Griffin Deborah A |
Chief Accounting Officer |
• – – |
2019-03-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,941 |
2,941 |
|
- |
|
| Fridriksdottir Hafrun |
Executive VP, Global R&D |
• – – |
2019-02-14 |
4 |
AS |
$17.67 |
$32,529 |
D/D |
(1,841) |
15,338 |
|
- |
|
| Fridriksdottir Hafrun |
Executive VP, Global R&D |
• – – |
2019-02-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,353 |
17,179 |
|
- |
|
| Sabag Mark |
EVP, Global Human Resources |
• – – |
2019-02-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,710 |
56,608 |
|
- |
|
| Codner Iris Beck |
EVP Global Brand&Communication |
• – – |
2019-02-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,212 |
17,996 |
|
- |
|
| De Notaristefani Carlo |
Executive VP Global Operations |
• – – |
2019-02-14 |
4 |
AS |
$17.67 |
$56,399 |
D/D |
(3,192) |
18,209 |
|
- |
|
| De Notaristefani Carlo |
Executive VP Global Operations |
• – – |
2019-02-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,280 |
21,401 |
|
- |
|
| Stark David Matthew |
Exec. VP Chief Legal Officer |
• – – |
2019-02-14 |
4 |
AS |
$17.74 |
$69,647 |
D/D |
(3,926) |
2,974 |
|
- |
|
| Stark David Matthew |
Exec. VP Chief Legal Officer |
• – – |
2019-02-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,926 |
6,900 |
|
- |
|
| De Notaristefani Carlo |
Executive VP Global Operations |
• – – |
2019-02-13 |
4 |
AS |
$17.88 |
$90,108 |
D/D |
(5,041) |
12,121 |
|
- |
|
| De Notaristefani Carlo |
Executive VP Global Operations |
• – – |
2019-02-12 |
4 |
A |
$0.00 |
$0 |
D/D |
14,432 |
17,162 |
|
- |
|
| Sabag Mark |
EVP, Global Human Resources |
• – – |
2019-02-12 |
4 |
A |
$0.00 |
$0 |
D/D |
9,381 |
50,898 |
|
- |
|
| Codner Iris Beck |
EVP Global Brand&Communication |
• – – |
2019-02-12 |
4 |
A |
$0.00 |
$0 |
D/D |
6,494 |
14,784 |
|
- |
|
| Fridriksdottir Hafrun |
Executive VP, Global R&D |
• – – |
2019-01-02 |
4 |
AS |
$15.70 |
$25,799 |
D/D |
(1,643) |
11,826 |
|
- |
|
| Fridriksdottir Hafrun |
Executive VP, Global R&D |
• – – |
2018-12-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,640 |
13,469 |
|
- |
|
| Fridriksdottir Hafrun |
Executive VP, Global R&D |
• – – |
2018-11-30 |
4 |
S |
$21.76 |
$20,304 |
D/D |
(933) |
8,829 |
|
- |
|
| Fridriksdottir Hafrun |
Executive VP, Global R&D |
• – – |
2018-11-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,711 |
9,762 |
|
- |
|
524 Records found
|
|
Page 18 of 21 |
|
|
0.16 (0.95%) 
